Paper40697666
CRISPR/Cas9 technology in tumor research and drug development application progress and future prospects.
Han H and 5 others. Front Pharmacol, 2025. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. CRISPR/Cas9 technology in tumor research and drug development application progress and future prospects. Papers, record 40697666. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40697666
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CRISPR/Cas9 technology in tumor research and drug development application progress and future prospects.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References178
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23979020 | Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. | Cell Res | 2013 | https://conductscience.org/library/papers/23979020 | PubMed |
| 2 | 36638795 | An evolved AAV variant enables efficient genetic engineering of murine T cells. | Cell | 2023 | https://conductscience.org/library/papers/36638795 | PubMed |
| 3 | 36856111 | CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer. | J Clin Invest | 2023 | https://conductscience.org/library/papers/36856111 | PubMed |
| 4 | 35953673 | High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects. | Nat Biotechnol | 2023 | https://conductscience.org/library/papers/35953673 | PubMed |
| 5 | 24433414 | Comparative analysis of RNAi screening technologies at genome-scale reveals an inherent processing inefficiency of the plasmid-based shRNA hairpin. | Comb Chem High Throughput Screen | 2014 | https://conductscience.org/library/papers/24433414 | PubMed |
| 6 | 26360417 | CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection. | PLoS One | 2015 | https://conductscience.org/library/papers/26360417 | PubMed |
| 7 | 19933107 | Breaking the code of DNA binding specificity of TAL-type III effectors. | Science | 2009 | https://conductscience.org/library/papers/19933107 | PubMed |
| 8 | 35619054 | Paired guide RNA CRISPR-Cas9 screening for protein-coding genes and lncRNAs involved in transdifferentiation of human B-cells to macrophages. | BMC Genomics | 2022 | https://conductscience.org/library/papers/35619054 | PubMed |
| 9 | 27956228 | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | Gastroenterology | 2017 | https://conductscience.org/library/papers/27956228 | PubMed |
| 10 | 30155824 | Non-transgenic Approach to Deliver ZFNs in Seeds for Targeted Genome Engineering. | Methods Mol Biol | 2018 | https://conductscience.org/library/papers/30155824 | PubMed |
| 11 | 26968626 | Use of the MS2 aptamer and coat protein for RNA localization in yeast: A response to "MS2 coat proteins bound to yeast mRNAs block 5' to 3' degradation and trap mRNA decay products: implications for the localization of mRNAs by MS2-MCP system". | RNA | 2016 | https://conductscience.org/library/papers/26968626 | PubMed |
| 12 | 39103848 | BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. | Mol Cancer | 2024 | https://conductscience.org/library/papers/39103848 | PubMed |
| 13 | 39426588 | CRISPR innovations in tissue engineering and gene editing. | Life Sci | 2024 | https://conductscience.org/library/papers/39426588 | PubMed |
| 14 | 37239814 | Engineering Human Cells Expressing CRISPR/Cas9-Synergistic Activation Mediators for Recombinant Protein Production. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37239814 | PubMed |
| 15 | 32219447 | Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia. | Blood | 2020 | https://conductscience.org/library/papers/32219447 | PubMed |
| 16 | 34954490 | CRISPR/Cas9-mediated demethylation of FOXP3-TSDR toward Treg-characteristic programming of Jurkat T cells. | Cell Immunol | 2022 | https://conductscience.org/library/papers/34954490 | PubMed |
| 17 | 25730490 | Highly efficient Cas9-mediated transcriptional programming. | Nat Methods | 2015 | https://conductscience.org/library/papers/25730490 | PubMed |
| 18 | 30923225 | Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution. | Science | 2019 | https://conductscience.org/library/papers/30923225 | PubMed |
| 19 | 36502574 | Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer. | EBioMedicine | 2023 | https://conductscience.org/library/papers/36502574 | PubMed |
| 20 | 34079130 | Base editing of haematopoietic stem cells rescues sickle cell disease in mice. | Nature | 2021 | https://conductscience.org/library/papers/34079130 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42893140 | Peptide-Mediated Precise Intracellular Delivery of Bioactive Substances. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42893140 | PubMed |
| 42539480 | CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions. | Front Oncol | 2026 | https://conductscience.org/library/papers/42539480 | PubMed |
| 42473674 | Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics. | Front Genet | 2026 | https://conductscience.org/library/papers/42473674 | PubMed |
| 42455481 | Decoding and Overcoming Temozolomide Resistance Through CRISPR/Cas Technologies. | Mol Diagn Ther | 2026 | https://conductscience.org/library/papers/42455481 | PubMed |
| 42135732 | Construction of a novel signature based on CRISPR-Cas9 screening for prognostic prediction in breast cancer. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42135732 | PubMed |
| 41756253 | RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41756253 | PubMed |
| 41595749 | Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential. | Biomedicines | 2026 | https://conductscience.org/library/papers/41595749 | PubMed |
| 41252108 | Mitochondrial-Based Nanomedicine in Treatment of Liver Cancer. | Mol Biotechnol | 2026 | https://conductscience.org/library/papers/41252108 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40697666
GET https://conductscience.org/api/papers/v1/40697666/references?page=2